MPW
LGND icon

MASECO Private Wealth’s Ligand Pharmaceuticals LGND Stock Holding History

MASECO Private Wealth’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-275
Closed -$52K – 497
2025
Q4 		$52K Hold
275
– – ﹤0.01% 174
2025
Q3 		$48.7K Hold
275
– – ﹤0.01% 92
2025
Q2 		$31.3K Buy
+275
New +$29.4K ﹤0.01% 213

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

MASECO Private Wealth's LGND Position: Q1 2026 in Review

MASECO Private Wealth sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 275 shares — an estimated $52K sold.

MASECO Private Wealth first reported a position in LGND in Q2 2025 and held it in 3 quarters. The position peaked at $52K in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • MASECO Private Wealth reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • MASECO Private Wealth sold 275 Ligand Pharmaceuticals shares in Q1 2026, an estimated $52K.
  • MASECO Private Wealth first reported a position in Ligand Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • MASECO Private Wealth's Ligand Pharmaceuticals position peaked at $52K in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on MASECO Private Wealth's 13F filing for Q1 2026, filed 21 Apr 2026.